| June 04, 2007 |
Announcement Regarding Conclusion of Cooperative Promotion Contract |
|
 |
|
As of June 4th, 2007, Goodman Company, Ltd. is pleased to announce the
conclusion of a cooperative promotion agreement with Johnson & Johnson
regarding the drug-eluting coronary stent “CYPHER sirolimus-eluting coronary
stent”. The details are as outlined below: |
|
|
|
1. Reason for Cooperative Promotion Agreement |
|
Through the effective application of organized cooperation between the
business foundation and excellent sales performance of Johnson & Johnson's
"CYPHER sirolimus-eluting coronary stent" with Goodman's powerful
sales network, we aim to further improve our mutual competitive strength. |
|
|
|
2. Cooperative Promotion Agreement Details |
|
To carry out “CYPHER sirolimus-eluting coronary stent” sales promotions
and safety measures at institutions selected for cooperative promotional
activity as agreed upon by both companies. |
|
|
|
3. Johnson & Johnson Corporate Outline |
|
| (1)Company Name |
Johnson & Johnson |
| (2)Business Focus |
Import, manufacture and sales of comprehensive medical treatment and health-related
products |
| (3)Date Established |
August, 1978 |
| (4)Head Office |
Chiyoda-ku, Nishi-Kanda 3-5-2, Tokyo |
| (5)Chief Representative |
Akira Matumoto |
| (6)Capital |
4 Billion Yen |
| (7)Employees |
1,852 (as of 12/2006) |
|
|
|
|
4. Schedule |
|
| 2007/5/28 |
Board of directors meeting |
| 2007/6/4 |
Execution of cooperative promotion agreement |
| 2007/7/1 |
Project commences |
|
|
|
|
5. Future Outlook |
|
We will make every effort to produce maximum results through the synergetic
effect gained from this cooperative promotion. As issues such as the circumstances
surrounding the DES market and the development status of competitor companies'
products are still uncertain, notifications will be provided as considered
necessary. |
